Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 

05 December 2017   CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY) wishes to advise in accordance with the terms and conditions of issue that the unquoted performance rights enclosed have lapsed and forfeited.   Download PDF for more

Download PDF
 
 

05 December 2017   We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.   Download PDF for more

Download PDF
 
 
Monday, 27 November 2017

Results of Meeting

27  November 2017 In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary. Download PDF for more

Download PDF
 
 
Monday, 27 November 2017

Managing Director’s AGM Presentation

27 November 2017   Today’s discussion outlines the CLINUVEL Board’s objectives to lead the growth of the Group by 2020. The emphasis today is on the strategic direction of the Group towards growth by 2020. Audiences unfamiliar with CLINUVEL are encouraged to review the website at www.clinuvel.com. Three elements have dictated CLINUVEL’s Board strategic considerations. […]

Download PDF
 
 

28 November 2017   Coming from the background of an ethical pharmaceutical company I had some misgivings 15 years ago of joining the board of a company with a ‘tanning’ drug. Here we are today, a genuine biopharmaceutical company having posted revenues of AUD$17.3m on a single drug used to treat an unusual orphan disorder. […]

Download PDF
 
 
Tuesday, 07 November 2017

Response to ASX Price Query

07 November 2018   Enclosed is the response of CLINUVEL PHARMACEUTICALS LTD in regards to a price query lodged by the ASX.   Download PDF for more

Download PDF
 
 
Sunday, 29 October 2017

Appendix 4C

29 October 2017   CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe and therapeutically unmet genetic disorders today announced its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2017.   […]

Download PDF
 
 

26 October 2017   This Explanatory Memorandum has been prepared for the Shareholders of the CLINUVEL PHARMACEUTICALS LIMITED ACN 089 644 119 in connection with the business to be conducted at the Annual General Meeting of Shareholders of the Company.   Download PDF for more

Download PDF
 
 
Thursday, 26 October 2017

Appendix 4G

26 October 2017   This statement reports on the main corporate governance practices of the Company as at 27 October 2017 and it has been approved by theBoard of the Company on 12 July 2017. This statement is organised under headings based on the Australian Securities Exchange CorporateGovernance Council’s (ASXCGC) Corporate Governance Principles and Recommendations, […]

Download PDF
 
 
Monday, 16 October 2017

CLINUVEL Newsletter – October 2017

16 October 2017   I am addressing you during quite a turbulent period, when our teams are preparing various dossiers to meet regulatory obligations in Europe and the US. As recently shared through the ASX, we are inching towards the complete new drug application (NDA) submission and are increasing the data package with European data […]

Download PDF
 
 
Monday, 09 October 2017

CLINUVEL CONFIRMS AGM DATE

10 October 2017   CLINUVEL PHARMACEUTICALS LTD  today announced it will hold its 2017 Annual General Meeting of shareholders on Tuesday 28 November 2017 at 10.00am AEDT at Arnold Bloch Leibler, Level 21, 333 Collins Street, Melbourne, Victoria, Australia 3000. A formal Notice of Meeting and the Company’s Annual Report will be lodged with the […]

Download PDF
 
 
Wednesday, 04 October 2017

ELIE ISHAG TO RETIRE FROM CLINUVEL BOARD

04 October 2017   CLINUVEL PHARMACEUTICALS LTD today announced that Mr Elie Ishag has advised that he will not stand for re-election as Non-Executive Director of CLINUVEL at the Company’s 2017 Annual General Meeting. He will continue to serve on the Board of CLINUVEL until the date of the Meeting.   Download PDF for more

Download PDF
 
 

19 September 2017   CLINUVEL PHARMACEUTICALS LTD  today announced an update on its submission of the New Drug Application (NDA) for CLINUVEL’s drug SCENESSE® (afamelanotide 16 mg) to the US Food and Drug Administration (FDA). EUROPEAN POST-MARKETING SAFETY DATA TO BE SUBMITTED AS PART OF NEW DRUG APPLICATION (NDA), EXPECTED IN DECEMBER 2017 NO RISK EVALUATION […]

Download PDF
 
 
Wednesday, 06 September 2017

Appendix 3B

 06 September 2017   Enclosed is a notice of a new issue announcement, application for quotation of additional securities and agreement   Download PDF for more

Download PDF
 
 

30 August 2017   CLINUVEL PHARMACEUTICALS LTD is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical […]

Download PDF
 
Friday, 09 October 2020

CLINUVEL Annual Report 2020

CLINUVEL’s Annual Report for the year ended 30 June 2020 is available to download here.

Download PDF
 
Friday, 09 October 2020

CLINUVEL Annual General Meeting 2020

CLINUVEL PHARMACEUTICALS LTD’s 2020 Annual General Meeting (AGM) will be held on Wednesday, 11 November 2020 at 06.00pm (Melbourne time). To comply with COVID19 requirements set out in Government restrictions on travel and public gatherings, …

Download PDF
 
Wednesday, 07 October 2020

SCIENTIFIC COMMUNIQUÉ VI

Despite government campaigns to curb increases, current statistics show the rate of skin cancer is escalating, particularly in regions with predominantly fair-skinned populations. Skin cancer diagnoses have increased considerably over the last five decades, at …

Download PDF
 
Tuesday, 06 October 2020

CLINUVEL News & Facts site live

Earlier this week CLINUVEL launched a new microsite, CLINUVEL News & Facts. The CLINUVEL News & Facts site gives an opportunity to explore and discuss the people, science and ideas that underpin CLINUVEL. Read more …

Download PDF
 
Monday, 28 September 2020

Kommuniqué V, 2020

Kommuniqué V, 2020

Download PDF
 
Wednesday, 23 September 2020

CLINUVEL Newsletter V

CLINUVEL Newsletter V, 2020

Download PDF
 
Thursday, 23 July 2020

Kommuniqué IV

Liebe Aktionäre, Freunde,Es stellt sich eine neue Welt dar, die darauf hinweist, dass das Virus nicht so leicht zu beseitigen sein wird. Waehrend wir es akzeptieren, einen Modus der Koexistenz zu finden, muessen wir für …

Download PDF
 
Wednesday, 22 July 2020

CLINUVEL Newsletter

Communiqué IV, 2020 – 22 July 2020 Dear shareholders, friends,As a new world presents itself indicating that the virus will not easily be eliminated as we are accepting to find a modus co-existentiae, albeit we …

Download PDF
 
Thursday, 21 May 2020

Kommuniqué III

Liebe Aktionäre, Freunde,Die außergewöhnlichen Zeiten, in denen wir leben, haben alle Kontinente beeinflusst. Jedes verlorene Leben war eins zu viel. Ich kann unseren italienischen medizinischen Kollegen, Patienten und Familien, die mit der Tragödie kämpfen, nicht …

Download PDF
 
Tuesday, 19 May 2020

CLINUVEL Newsletter

Dear shareholders, friends,The extraordinary times in which we are living have affected all continents. Each life lost has been one too many. I cannot express enough empathy to our Italian medical colleagues, patients and families …

Download PDF